China’s central bank injected CNY900 billion via its Medium-Term Lending Facility, signaling ongoing support for bank funding and credit growth. The move aims to stabilize liquidity as authorities balance a property downturn with efforts to sustain activity ahead of key trade and policy events. Markets are watching for follow-through in lending data and any guidance on further easing.
Source: SeekingAlpha
Moody’s cuts France’s outlook to negative amid political fragmentation risks
Moody’s shifted France’s sovereign outlook to negative, citing fiscal slippage and political fragmentation that could complicate consolidation. The change highlights Europe’s widening growth and budget divergences, potentially affecting French bond spreads and the euro if fiscal anchors weaken further. Investors will look to the upcoming budget cycle for credible deficit-reduction plans.
Source: SeekingAlpha
U.S.–China trade thaw: soybean buying resumes as leaders eye deal
Washington and Beijing signaled progress toward a trade accord, with China resuming U.S. soybean purchases ahead of a Trump–Xi meeting. Any de-escalation could ease tariff uncertainties, support commodity flows, and improve risk appetite as investors also brace for the Fed decision and a heavy week of megacap earnings. The durability of the thaw will hinge on concrete deliverables beyond agricultural buys.
Source: SeekingAlpha
HSBC to book US$1.1B provision tied to Madoff cases; capital hit flagged
HSBC said it will set aside US$1.1 billion in Q3 following a Luxembourg ruling related to Bernard Madoff-linked litigation, implying a ~15 bps impact to its CET1 ratio. The bank maintained guidance on dividends and returns, but the provision underscores lingering legal tail risks across global lenders. Investors will parse Q3 results for balance-sheet resilience amid Hong Kong property stress and broader credit trends.
Source: SCMP
Novartis to acquire Avidity Biosciences in $12B deal to expand rare-disease pipeline
Novartis agreed to buy Avidity Biosciences for roughly $12 billion, bolstering its muscular and rare-disease portfolio with RNA-targeted therapies. The premium deal extends Big Pharma’s push into genetic medicines and could catalyze further biotech M&A after a volatile year for small-cap drug developers. Execution on late-stage trials and regulatory timelines will be key to value realization.
Source: SeekingAlpha
Japan launches first yen-backed stablecoin under new rules
Tokyo-based JPYC unveiled the first fully regulated yen-pegged stablecoin under Japan’s amended Payment Services Act, backed by bank deposits and JGBs. The move positions Japan at the forefront of compliant fiat-token issuance in developed markets, opening pathways for programmable payments and tokenized finance. Adoption will depend on integration with banks, payment rails, and DeFi platforms.
Source: FinanceFeeds
Western Union to pilot stablecoin settlements to speed cross-border flows
Western Union plans to test stablecoin-based on-chain settlements for treasury operations, seeking faster cross-border transfers, lower friction, and improved liquidity management. While consumer-facing use may come later, the pilot underscores traditional finance’s shift toward blockchain rails under a compliance-first model. Successful tests could pressure peers to accelerate digital settlement strategies.
Source: FinanceFeeds
You May Also Be Interested In…
- Stock futures rise ahead of Big Tech earnings, Trump–Xi meet, and the Fed
- Citigroup opens Riyadh regional HQ as Wall Street deepens Saudi presence
- Barclays returns to Saudi Arabia after 11-year absence
- Dangote to more than double Nigeria refinery capacity
- Robinhood to launch futures trading for UK customers